… release (IR) and extended release (ER) formulations, and ER MPH has become increasingly
dominant in recent years [19, 20]. Osmotic release oral system … and equivalent effectiveness …

… An open-label, four-arm, Phase 2a trial to test the efficacy of … accumulated by halophile
bacteria to withstand osmotic stress [Citation58]. … The results of a prospective, active-controlled, …

… al. formulated an osmotic release strategy of cyclosporine via … In a randomized, active-controlled
phase 2/3 study, tregopil … First of all, a prospective, single-center, open-label, phase 1 …

… Arbaclofen extended-release (ER) employs osmotic pump technology to … , randomized
placebo- and active-controlled trial demonstrated that 40 mg/day arbaclofen ER had similar …

… of receiving osmotic-release oral system methylphenidate (… head randomized clinical trial
was a 24-week open-label study… Similar findings were noted in the RVIP. The probability of …

… , randomized, rater-blinded, active-controlled trial conducted … Similar to the present study,
in a large, population-based cohort … Two open-label trials have demonstrated improved …

… was developed using an oral osmotic pump technology. Later… were generated in an open-label,
randomized, phase I study … a double-blind, randomized, active-controlled, parallel-group …

… osmotic release oral system (OROS) MPH in a 6-week, randomized, double-blind, placebo-
and active-controlled … Similarly, an 8- to 10-week, open-label, head-to-head, randomized trial …

… -release MPH (IR-MPH) and osmotic-release oral system MPH … 14 days, (ii) the open-label
titration period, which lasted 2–4 … Similar to the results for the SNAP-IV-T analysis, we found …

… randomly assigned to osmotic-release oral system methylphenidate (n = 83) and atomoxetine
(n = 85) in a 24-week, open-label, head-to-head clinical trial. … have comparable efficacy in …